on Relief Therapeutics Holding SA (ETR:RLF)
MindMaze Therapeutics Gains Baader Bank Coverage
MindMaze Therapeutics Holding SA, a leading global entity in brain technology and neurotherapeutics, announced that Baader Bank has begun equity research coverage on its shares. This action includes a Buy recommendation and sets a target price of CHF 1.80 per share. This new analysis joins existing coverage by Edison Group, which currently values the company at CHF 3.56 per share.
MindMaze Therapeutics is recognized for its innovation in digital treatments for neurological conditions, employing advanced technology like AI-driven data analytics and proprietary sensors. Their products, which are FDA-cleared and CE-marked, tackle a shortage of specialized clinicians by providing scalable solutions for stroke and Parkinson's disease.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Relief Therapeutics Holding SA news